Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a ...
FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction
BeiGene (NasdaqGS:ONC) experienced a significant 29% price increase over the last quarter, supported by the FDA approval of TEVIMBRA for treating esophageal squamous cell carcinoma, a key development ...
The Pharma Letter22h
IN8bio moves into autoimmune space with new TCE platform
IN8bio has unveiled a new T cell engager (TCE) platform, marking its first major push into autoimmune disease. The biotech, which previously focused on oncology, introduced INB-619, a CD19-targeted ...